anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Multiple factors are involved in the pathogenesis of primary biliary cholangitis (PBC), a chronic cholestatic liver disease, characterized by intrahepatic cholangiopathy. In particular, studies have suggested that environmental factors such as the presence of granulomas in the portal vein region are important for the development of PBC. This study aimed to comprehensively analyze and identify foreign-derived antigens in PBC liver tissue to confirm their involvement in PBC pathogenesis.
METHODS: Portal areas and hepatocyte regions were selectively dissected from formalin-fixed paraffin-embedded PBC liver tissue samples using the microlaser method, followed by total DNA extraction. We then validated whether the bacterial strains identified through 16S rRNA metagenomic analysis were detected in PBC liver tissues.
RESULTS: The most frequently detected bacterial genera in the PBC liver tissue samples were Sphingomonas panacis, Providencia, and Cutibacterium. These bacterial genera were also detected in the other PBC samples. Validation for the detection of S. panacis, the most abundant genus, revealed polymerase chain reaction bands extracted from the portal areas of all samples. They were also more highly expressed than bands detected in the hepatocyte region.
CONCLUSION: S. panacis antigen was specifically detected in the portal areas of PBC liver tissues. The introduction of foreign-derived antigens into the liver as an environmental factor could be a possible mechanism for the development of PBC.
A traditional Chinese medicine prescription for treating intercostal neuralgia is disclosed. Each dosage of the prescription is prepared from following medicine materials by mass: 18-25 g of danshen root, 12-20 g of Chinese thorowax root, 15-25 g of Chinese angelica, 15-25 g of debark peony root, 15-25 g of finger citron, 15-25 g of rhizoma corydalis, 15-25 g of radix platycodonis, 5-10 g of licorice root, 15-20 g of orange fruit and 1-2 g of radix notoginseng powder. After other medicine materials are decocted, the radix notoginseng powder is added, and the product is taken once in the morning and evening respectively. Through reasonably compatibility of the medicine materials in the prescription, the prescription has effects of clearing the liver, regulating qi, removing stasis and arresting bleeding and can be used for treating the intercostal neuralgia caused by blood stasis stagnation, blocked collaterals and weak circulation of qi and blood. The prescription can improve human body vital qi, promote qi and blood circulation and boost immunity of human bodies. One treatment course includes one week. The effective rate of the one treatment course is 91%. Adverse effects are not generated in a taking process of the traditional Chinese medicine by the patients.
FIELD: medicine. 
     SUBSTANCE: invention refers to medicine, x-ray diagnostics, and can be used in processing of MR images with delayed contrasting, determining the structure of the left atrial myocardium (LM) in the patients with atrial fibrillation (AF). It is necessary to perform MRT of the heart with delayed staining. On the basis of the obtained series of images one performs multi-plane reconstruction of LM in three mutually perpendicular planes: frontal, sagittal, axial. On the basis of multi-plane reconstruction data one performs searching of cardiac structures and artefacts, which can be mistaken for LM myocardium, in the following sequence. First, one determines topography of LM and adjoining structures, for which purpose it is necessary to determine topography of the mitral ring in the obtained planes, the first layer of atrial myocardium is immediately above the level of ring of mitral valve. Then, on the axial plane, one draws a longitudinal axis of the left ventricle (LV) and its transverse axis at the level of the mitral valve. Along the constructed transverse axis of LV at all axial sections of LM one draws the boundary between LV and LM. Then one determines the oesophagus and its boundary with the back wall of LM. One determines the aortic valve ring, descending aorta, differentiating these structures with LM wall in places of their closest location. One determines the route of the left coronary artery near LM loop as a band of an intensive signal migrating from layer to layer towards lateral wall of LV. Then one outlines LM contours, for which purpose it is necessary to first outline LM endocardial contour using as a reference point LM back wall. Then one outlines the atrial myocardium in the medial direction and backwards from the defined boundary between LM and LV. Front wall and LM loop are outlined above the upper boundary of the ring of mitral valve. Then one outlines LM epicardial circuit. Finally, one excludes artefacts, for which purpose he detects in LM myocardium zones with brightness more intense than brightness of the wall of the aorta in this layer. One views such zones in different planes while interpreting the zone as not related to LM myocard. Such zone is manually cut out from its boundaries. 
     EFFECT: this method makes its possible to accurately outline LM myocard contour and ensures standardization of procedure of working with MR-images, which allows to obtain comparable results. 
     3 cl, 8 dwg
Patients will first receive an abbreviated course of three cycles of fludarabine (25 mg/m2 for 5 days every 5 weeks). Iodine I 131 tositumomab will be initiated 6 to 8 weeks after completion of fludarabine. Patients will undergo dosimetry studies to determine the appropriate patient-specific activity of iodine I 131 tositumomab required to deliver a fixed dose of 75 cGy. The dose will be attenuated to 65 cGy for patients with platelet counts between 100,000 and 150,000/micoliter.
Acetyl salicylic acid (I) is powdered, but readily rehydrated form, is prepd. by pyophilisation of a sln. of (I) is dioxan. Used for parenteral admin. (I) for use as an antipyretic, analgesic etc., the powdered form of (I) is readily soluble, giving a clear soln. It is perfectly stable and will not hydrolyze on storage.
A prospective randomized clinical trial to determine if using liposomal bupivicaine in maxillary orthognathic procedures can reduce the post-operative use of opioids as well as improving the patient's quality of life versus traditional bupivicaine alone. A total of 100 patients who would ordinarily undergo maxillary orthognathic procedures will be randomized into 2 groups. One group will receive 133mg of Exparel (must limit volume of product due to spaces involved and other studies in oral surgery have used 133mg) at the completion of the procedure while the control group receives 50 mg of bupivicaine at the completion of the procedure as is typical standard of care. The injections will be made in similar regions near the incision lines. No other differences will be made between the groups. Perioperative anesthesia will consist of non-opioid techniques, and patients will be monitored post-operatively during a 1 night hospital admission. Patients will complete an anonymous daily diary for 7 days. The diary will consist of information regarding pain scores, quality of life (nausea, swelling, oral function, etc) and medicines taken.

At one week post op the participant will return to the clinic where they will fill out a final questionnaire discussing the previous week's experience regarding the topics of the questionnaires.
Patients with Alzheimer's disease (AD) have gut dysbiosis. Short-chain fatty acids (SCFAs) are products of the gut microbiome. Among them, Acetate and valeric acid were positively correlated with the Aβ plaque load detected by amyloid PET in participants with or without AD. However, the levels of SCFAs in the blood of patients with AD have not been defined. Also, the usefulness of indices of inflammation and neuropathology in the blood as biomarkers for cognitive impairment in patients with AD is elusive. Importantly, spousal caregivers of patients with dementia have a higher risk of developing dementia later in life than those whose spouses do not have dementia. The spousal caregivers have an accelerated cognitive decline. The mechanisms for these phenomena are not known. We hypothesize that spousal caregivers of patients with AD have gut microbiome and levels of blood SCFAs similar to those of patients with AD, that these spouses have increased inflammatory cytokines and indices of AD-like neuropathology in the blood, and that there is a correlation between the cognition and various indices in the blood among patients with AD, their spouses, and age-matched controls. To address these hypotheses, we will recruit three groups of participants: Patients with AD, their spousal caregivers, and controls that are age-matched with the caregivers. Their gut microbiome and indices of neuroinflammation and neuropathology in the blood will be determined. Their cognition will be assessed. The correction of cognition with gut microbiome genera or indices in the blood will be analyzed. Our studies may represent the first study to determine whether the gut microbiome and SCFAs may play a role in the cognitive impairment in the spousal caregivers of patients with AD. These studies may also identify biomarkers for cognitive impairment in these caregivers and patients with AD. These findings may ultimately help the care of patients with AD and reduce the cognitive declines in spousal caregivers of patients with AD.
The multidomain intervention will combine a cognitive training with aerobic and resistance exercises training, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
A method is described for determining a disease progression and survival prognosis, at a succession of prediction times, for patients suffering from amyotrophic lateral sclerosis (ALS). The method comprises a step of defining a set of variables associated with the onset and progression of amyotrophic lateral sclerosis, comprising a first group of variables associated with the onset of amyotrophic lateral sclerosis (comprising at least the variables "patient sex", "disease onset age", "disease onset site"), a second group of dynamic time variables (comprising at least the variable "time elapsed since disease onset"), a third group of dynamic functional variables (comprising at least one of the variables breathing, swallowing, communicating, walking/self-care or at least one variable of a functional progression and/or severity scale of amyotrophic lateral sclerosis), and further at least one variable associated with survival. The method further provides for encoding by means of a Dynamic Bayesian Network, using at least one trained algorithm, a plurality of probabilistic conditional dependence relationships, in which each relationship is a probabilistic conditional dependence relationship between two of the aforesaid variables. The aforesaid prediction times are defined so that each prediction time belongs to a respective time interval in which the conditional dependence relationships between the variables are stationary. The method further involves describing the Dynamic Bayesian Network, using at least one trained algorithm, by means of a corresponding graph, comprising said variables as nodes and comprising topological connections oriented between nodes corresponding to variables among which a probabilistic conditional dependence is identified. In the graph, given a node, the connections entering it show a conditional probability of the value assumed by the variable associated with such node, in a given prediction time, depending on the values assumed, in a prior prediction time, from the variables associated with the nodes from which such connections originate. The method further comprises the steps of entering, for each of the defined variables, data acquired at a given acquisition time relating to the situation of a specific patient; and calculating, by electronic processing and/or calculating means, on the basis of the Dynamic Bayesian Network and the graph, and starting from the aforesaid acquired data, the values of each of the defined variables, at one or more prediction times following the acquisition time. Finally, the method involves obtaining, in a given prediction time, disease progression prognosis results on the basis of the values of one or more of the variables of the third group calculated in such prediction time; and the survival prognosis results on the basis of the value of at least one variable associated with survival, calculated at such prediction time.
TAU + experimental intervention. The experimental group will receive all services provided to the TAU group (described above) and, additionally, the experimental intervention.The intervention includes 1 individual session for each teen and parent and 2 family sessions (focused on psychoeducation and motivational enhancement) with both the teen and parent, delivered during hospitalization (\~45-60 minutes per session).
The invention relates to an external used medicine for treating burn, and a preparing method thereof. The medicine is characterized by being prepared from the following raw materials in parts by weight: 20 parts of coptis root, 25 parts of phellodendron, 25 parts of Baikal skullcap root and 30 parts of ox-gall. The preparing method comprises the following steps of: crushing the coptis root, phellodendron, Baikal skullcap root and ox-gall; adding balm to mix into paste for external use. The selected drugs have the efficiency on clearing heat and relieving dampness and purging fire for detoxifying by functioning together. The medicine has good curative effect on light burns. Proved by clinic application, the medicine has the advantages of quick action, obvious curative effect and no toxic or side effect.
OBJECTIVE: Artificial intelligence (AI) detects heart disease from images of electrocardiograms (ECGs). However, traditional supervised learning is limited by the need for large amounts of labeled data. We report the development of Biometric Contrastive Learning (BCL), a self-supervised pretraining approach for label-efficient deep learning on ECG images.
MATERIALS AND METHODS: Using pairs of ECGs from 78 288 individuals from Yale (2000-2015), we trained a convolutional neural network to identify temporally separated ECG pairs that varied in layouts from the same patient. We fine-tuned BCL-pretrained models to detect atrial fibrillation (AF), gender, and LVEF < 40%, using ECGs from 2015 to 2021. We externally tested the models in cohorts from Germany and the United States. We compared BCL with ImageNet initialization and general-purpose self-supervised contrastive learning for images (simCLR).
RESULTS: While with 100% labeled training data, BCL performed similarly to other approaches for detecting AF/Gender/LVEF < 40% with an AUROC of 0.98/0.90/0.90 in the held-out test sets, it consistently outperformed other methods with smaller proportions of labeled data, reaching equivalent performance at 50% of data. With 0.1% data, BCL achieved AUROC of 0.88/0.79/0.75, compared with 0.51/0.52/0.60 (ImageNet) and 0.61/0.53/0.49 (simCLR). In external validation, BCL outperformed other methods even at 100% labeled training data, with an AUROC of 0.88/0.88 for Gender and LVEF < 40% compared with 0.83/0.83 (ImageNet) and 0.84/0.83 (simCLR).
DISCUSSION AND CONCLUSION: A pretraining strategy that leverages biometric signatures of different ECGs from the same patient enhances the efficiency of developing AI models for ECG images. This represents a major advance in detecting disorders from ECG images with limited labeled data.
The Combined strengthening group will perform the same isolated strengthening exercises, but with the addition of proximal strengthening exercises for the hip and core muscles. These exercises include 10 repetitions of bridging(3 sets), 10 repetitions of clamshells(2 sets), 10 repetition of 3 sets of legs extensions,10 repetition of 3 sets squats,10 repetition of 3 sets lunges and 10 repetitions of planks(2 sets).
Patients receive dinaciclib IV over 2 hours and bortezomib SC or IV (if patients do not tolerate SC injection) on days 1, 8, and 15 and dexamethasone PO QD on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients receive fludarabine phosphate IV over 30 minutes on days -9 to -6, busulfan IV over 3 hours on days -5 to -2, and anti-thymocyte globulin IV over 6 hours on days -3 and -2 and over 4 hours on day -1. Patients undergo allogeneic PBSC transplant on day 0. Patients then receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and taper to day 180 and methotrexate IV on days 1, 3, 6, and 11.
Improvement and worsening of portal hypertension after direct acting antiviral agent (DAA) treatment for hepatitis C virus-related cirrhosis have been reported, and a consensus remains elusive. In this study, we underscored on the intraperitoneal shunt formed via portal hypertension and examined how the shunt system confirmed by computed tomography (CT) changes before and after treatment in cases in which sustained virological response (SVR) was attained with DAAs. Of the cases in which we achieved an SVR of 24 with DAA treatment for hepatitis C virus-related cirrhosis at our hospital, 83 cases in which CT images were taken before and after treatment were investigated. If the intraperitoneal shunt diameter changed by 20% or more, it was analyzed as an increase or decrease. In 29 patients, intraperitoneal shunt enlargement was noted. When examining factors related to the increase, multivariate analysis detected the FIB4 index at the end of the DAA treatment. Conversely, only four cases were observed in which the size decreased. At the end of treatment, the FIB4 index was the most important factor in increasing the intraperitoneal shunt after DAA treatment for hepatitis C virus-related cirrhosis, and fibrosis was believed to be an influencing factor.
Investigators will compared results intra and extraperitoneal cesarean section. Two groups will determine according to random numbers table. After operations, blood count, C reactive proteins, postoperative temperature, need for analgesia, ileus, bowel movement, mobilization time will compare by blind physician. Abdominal, shoulder and incisional pain at postoperative 0, 6, 12, 18, 24, 30 hours will compared by use visual analog score. Neonatal results and complications also will compare. Investigators and participants will be blind regarding technique.
PURPOSE: With aging and age-related macular dystrophy (AMD), proteolytic fragments are deposited in extracellular drusen located between the RPE and Bruch's membrane. Localized hypoxia may be a risk factor for AMD. Our hypothesis is that following hypoxia, activation of proteolytic enzymes called calpains may cause proteolysis/degeneration of retinal cells and RPE. No direct evidence has yet demonstrated activation of calpains in AMD. The purpose of the present study was to identify calpain-cleaved proteins in drusen.
METHODS: Seventy-six (76) drusen were analyzed in human eye sections from six normal and twelve AMD human donor eyes. The sections were subjected to immunofluorescence for the calpain-specific 150 kDa breakdown product from α-spectrin, SBDP150 - a marker for calpain activation, and for recoverin - a marker for photoreceptor cells.
RESULTS: Among 29 nodular drusen, 80% from normal eyes and 90% from AMD eyes stained positive for SBDP150. Among 47 soft drusen, mostly from AMD eyes, 72% stained positive for SBDP150. Thus, the majority of both soft and nodular drusen from AMD donors contained SBDP150.
CONCLUSIONS: SBDP150 was detected for the first time in soft and nodular drusen from human donors. Our results suggest that calpain-induced proteolysis participates in the degeneration of photoreceptors and/or RPE cells during aging and AMD. Calpain inhibitors may ameliorate AMD progression.
Genetic regulation of neonatal pulmonary surfactant deficiency has been suggested by studies of gender, genetic linkage, recurrent familial cases, targeted gene ablation in murine lineages, and by racial disparity in risk of neonatal respiratory distress syndrome. Successful fetal-neonatal pulmonary transition requires production of the pulmonary surfactant, a phospholipid-protein film that lines alveoli and maintains alveolar patency at end expiration. Our goal is to understand the genetic mechanisms that disrupt pulmonary surfactant metabolism and cause neonatal respiratory distress syndrome. Studies in human newborn infants have demonstrated that 3 genes are critical for surfactant metabolism: surfactant protein B (SFTPB), surfactant protein C (SFTPC), and an ATP-binding cassette transporter, ABCA3 (ABCA3). To understand genetic regulatory mechanisms, we will investigate the contribution of variation in each of these genes to risk of neonatal respiratory distress syndrome by testing the hypothesis that genetic variants in the SFTPB, SFTPC, and ABCA3 disrupt pulmonary surfactant metabolism. Using high throughput automated sequencing to genotype, multidimensional protein identification technology to assess quantitative and qualitative differences in surfactant protein B and C expression, in vivo metabolic labeling with stable isotopically labeled precursors to estimate surfactant protein B and C and phospholipid metabolic rates, and cohort sizes that provide statistical power (0.8), we will use race-specific, severity-stratified case-control (N=480) and case comparison (N=250) designs to understand genetically regulated, metabolic mechanisms that cause surfactant deficiency by disrupting expression or altering processing of surfactant proteins B or C or by disrupting surfactant phospholipid composition in human newborn infants. Improved understanding of genetic regulation of surfactant deficiency will suggest novel diagnostic strategies to identify and categorize high risk infants and therapeutic strategies that target discrete steps in pulmonary surfactant metabolism to improve outcomes of infants with neonatal respiratory distress syndrome.
A young man in his early 20s presented with extraoral swelling on left side of his face, which had been present for a period of 1 month. Intraoral examination revealed an erythematous swelling on the left side of floor of the mouth at the ductal opening of left submandibular salivary gland. On palpation, multiple firm masses were noted, and pus mixed with blood was discharged from the ductal opening. He reported a history of swelling occurring in the same region, which was associated with mild fever and subsided after taking antibiotics. Keeping the history in mind, multiple radiographical investigations were carried out, focusing on the submandibular salivary gland. These investigations revealed the presence of salivary calculi, also known as salivary stones or sialolith, in the ductal pathway, causing obstruction to the glandular parenchyma. Hence, a final diagnosis of obstructive chronic bacterial sialadenitis was made. The case was treated surgically due to the size of the salivary stones, in combination with a preoperative antibiotic course. Multiple stones were retrieved and the incision was sutured. Complete healing was noted in a span of 2 weeks. This case report highlights the effectiveness of conventional imaging modalities in early diagnosis compared with advanced imaging techniques. By using conventional imaging, the case was managed with a simple surgical procedure rather than the more invasive option of removing the entire gland, thereby preserving the patient's quality of life. This case report underscores the importance of clinical examination and selecting appropriate investigative tools for early diagnosis, supported by a comprehensive literature review.